Strategic Site Selection for Biopharmaceutical Companies at Different Development Stages

The biopharmaceutical industry in China encompasses various fields of development, each at different stages of maturity. This article explores the site selection considerations for biopharmaceutical companies based on their respective areas of focus and development stages. The key areas discussed include research-focused enterprises in cell therapy and gene therapy, industry-transformation stage companies in antibody drugs, and stable industrialized enterprises in vaccines, recombinant proteins, and blood products.

1. Research-Focused Enterprises: Cell Therapy and Gene Therapy
Companies involved in cell therapy and gene therapy are predominantly in the early stages of clinical development or preclinical research. These enterprises require substantial investments in research and process development, necessitating resources such as research laboratories, small-scale production facilities, office spaces, and capital infusion from the industry. The site selection for such companies should prioritize access to research facilities, collaboration with academic institutions, and availability of venture capital funding.

2. Industry-Transformation Stage Enterprises: Antibody Drugs
Antibody drug companies in China have witnessed some products reaching the market, with a considerable number of projects in the later stages of clinical trials, indicating relative maturity. These enterprises require both significant R&D investments and facilities for pilot-scale and large-scale production. Site selection considerations for antibody drug companies involve obtaining product registration approvals, assessing clinical research progress, and analyzing investment and financing data to facilitate the transition to industrialization.

3. Stable Industrialized Enterprises: Vaccines, Recombinant Proteins, and Blood Products
Enterprises involved in vaccines, recombinant proteins, and blood products have obtained market approvals for a substantial number of products. These companies primarily focus on production investments and operate in highly regulated environments with stringent quality requirements. Site selection for these stable industrialized enterprises encompasses considerations such as research laboratories, office spaces, pilot-scale and industrial-scale production facilities, and proximity to supportive ancillary services.

Site Selection Sensitivities for Biopharmaceutical Companies:

Common Considerations:
1. Funding Support: Local governments and industrial parks can provide financial assistance or equity investments through industry funds to support R&D and clinical trials.
2. Infrastructure: Provision of GMP-compliant manufacturing facilities with floor area requirements typically ranging from 2,000 to 5,000 square meters.
3. Local Industrial Ecosystem: Availability of upstream bioreagents, access to midstream innovation drug public service platforms, and the presence of downstream hospitals.
4. Ancillary Support: Availability of laboratories, warehouses, waste management facilities, among others.
5. Hospital Resources: For gene/cell therapy companies, collaborations with hospitals and expansion of the local market are crucial.

Differences in Considerations:
1. Antibody Drugs and Recombinant Proteins: Availability of local innovative resources, research capabilities, and the establishment of flexible manufacturing lines under the backdrop of intelligent manufacturing.
2. Vaccines: Market potential, convenient transportation, logistics, and a broad local market base.
3. Cell Therapy: Reliance on cell bank resources, proximity to cell storage facilities, and the presence of qualified downstream clinical institutions.

Site selection for biopharmaceutical companies in China varies based on the specific development stage and focus area. While there are common considerations such as funding support, infrastructure, and local industrial ecosystems, certain nuances exist depending on the field of specialization. By strategically aligning their site selection with the requirements of their development stage, biopharmaceutical companies can optimize their operations, foster innovation, and contribute to the growth of the industry.